NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

免疫毒素市場(2021年-2026年)

Immunotoxin Market (2021 - 2026)

出版商 IndustryARC 商品編碼 996445
出版日期 內容資訊 英文 99 Pages
商品交期: 2-3個工作天內
價格
免疫毒素市場(2021年-2026年) Immunotoxin Market (2021 - 2026)
出版日期: 2020年12月23日內容資訊: 英文 99 Pages
簡介

根據世界衛生組織(WHO),2012年的癌症的死亡人數是820萬人,成為全球死因的第1位。全球中,先進有效率的技術開發,政府的配合措施增加,全球各地的癌症的發生率增加,成為全球免疫毒素市場主要的成長因素。還有非醫療用途的免疫毒素的採用增加,及中國,印度等的新興國家,將帶給全球免疫毒素市場新機會。

本報告提供全球免疫毒素市場相關調查,市場概要,市場形勢,市場影響要素,各市場區隔,及地區市場相關分析,並提供主要企業簡介等資訊。

目錄

第1章 免疫毒素市場-市場概要

第2章 摘要整理

第3章 市場形勢

  • 市場佔有率分析
  • 比較分析
  • 產品的基準
  • 終端用戶分析
  • 前五名公司的財務分析

第4章 免疫毒素市場-市場影響要素

  • 促進因素
    • 高度有效率的技術的開發
    • 政府措施增加
    • 在全球癌症的發生率增加
  • 阻礙因素
    • 高投資成本
    • 計劃的非有效率的實行
  • 市場機會
    • 新興經濟國
    • 對非醫療用途的免疫毒素的採用增加
  • 課題
  • 波特的五力分析

第5章 按毒素的免疫毒素市場

  • 綠色膿菌外毒素(PE)
  • 白喉毒素(DT)

第6章 各終端用戶的免疫毒素市場

  • 醫療保健
  • 研究
  • 其他

第7章 各地區的免疫毒素市場

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 英國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 其他地區(RoW)
    • 巴西
    • 其他

第8章 免疫毒素-市場熵

  • 擴張
  • 技術開發
  • 合併和收購,及合資企業
  • 供給契約

第9章 企業簡介簡介,財務,主要的洞察,主要的策略,產品系列,SWOT分析)

  • Abbott Point of Care, INC.
  • Acon Laboratories, INC.
  • Bayer AG
  • F. Hoffman La-Roche LTD.
  • Lifescan, INC.
  • Medtronic INC.
  • Nova Biomedical Corporation
  • Pharmaco-Kinesis Corporation
  • Siemens AG
  • Creative Biolabs
目錄
Product Code: HCR 0239

Immunotoxins are proteins which are manmade, include a toxin along with an antibody or growth factor that go through endocytosis, and the toxin kills the cell. Immunotoxins are usually made of a modified antibody or antibody fragment, attached to a fragment of a toxin. Immunotoxins are used for the treatment of some kinds of cancer and a few viral infections. According to World Health Organization (WHO) in 2012, Cancers accounted for 8.2 million deaths, and was the leading causes of death worldwide. Globally, development of advance and efficient technology, rise in the government initiatives, and increasing incidences of cancer around the globe are the prime growth drivers of global immunotoxins market. In addition, increase in adoption of immunotoxins for non-medical applications, and emerging economies such as China, India and others, will create new opportunities for global immunotoxins market. However, higher cost of the research and development, and inefficient execution of plan are the key restraints for global immunotoxins market.

This report identifies the global immunotoxins market size in for the year 2014-2016, and forecast of the same for year 2026. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global immunotoxins market.

Geographically North America dominated global immunotoxins market, and Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population, rising incidence of cancer, and modernizing healthcare infrastructure in developing nations such as, China, and India in this region. Among all the end-users, healthcare segment has the highest market share in global immunotoxins market.

This report segments global immunotoxins market on the basis of toxins, end-user, and regional market as follows:

  • Immunotoxins Market, By Toxins: Pseudomonas Exotoxin (PE), and Diphtheria Toxin (DT)
  • The report has focused study on immunotoxins market by basis of end-user such as: Healthcare, Research Labs, and Others

This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the immunotoxins market. Some of the major companies' profiles in detail are as follows:

  • Abbott Point of Care, INC.
  • Acon Laboratories, INC.
  • Bayer AG
  • F. Hoffman La-Roche LTD.
  • Lifescan, INC.

Table of Contents

1. Immunotoxins Market - Market Overview

2. Executive Summary

3. Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Immunotoxins Market- Market Forces

  • 4.1. Drivers
    • 4.1.1. Development of advance and efficient technology
    • 4.1.2. Rise in the government initiatives
    • 4.1.3. Increasing incidences of cancer around the globe
  • 4.2. Restraints
    • 4.2.1. Higher cost of investment
    • 4.2.2. Inefficient execution of plan
  • 4.3. Opportunities
    • 4.3.1. Emerging economies
    • 4.3.2. Increase in adoption of immunotoxins for non-medical applications
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Immunotoxins Market, By Toxins

  • 5.1. Pseudomonas Exotoxin (PE)
  • 5.2. Diphtheria Toxin (DT)

6. Immunotoxins Market, By End-User

  • 6.1. Healthcare
  • 6.2. Research Labs
  • 6.3. Others

7. Immunotoxins Market, By Geography

  • 7.1. Europe
    • 7.1.1. Germany
    • 7.1.2. France
    • 7.1.3. Italy
    • 7.1.4. Spain
    • 7.1.5. Russia
    • 7.1.6. U.K.
    • 7.1.7. Rest of Europe
  • 7.2. Asia Pacific
    • 7.2.1. China
    • 7.2.2. India
    • 7.2.3. Japan
    • 7.2.4. South Korea
    • 7.2.5. Rest of Asia-Pacific
  • 7.3. North America
    • 7.3.1. U.S.
    • 7.3.2. Canada
    • 7.3.3. Mexico
  • 7.4. Rest of the World (RoW)
    • 7.4.1. Brazil
    • 7.4.2. Rest of RoW

8. Immunotoxins - Market Entropy

  • 8.1. Expansion
  • 8.2. Technological Developments
  • 8.3. Merger & Acquisitions, and Joint Ventures
  • 8.4. Supply- Contract

9. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)

  • 9.1. Abbott Point of Care, INC.
  • 9.2. Acon Laboratories, INC.
  • 9.3. Bayer AG
  • 9.4. F. Hoffman La-Roche LTD.
  • 9.5. Lifescan, INC.
  • 9.6. Medtronic INC.
  • 9.7. Nova Biomedical Corporation
  • 9.8. Pharmaco-Kinesis Corporation
  • 9.9. Siemens AG
  • 9.10. Creative Biolabs